Filgo sales stonden samen met meerdere medicijnen in de cijfers van Gilead. Valt weinig uit op te maken.
"Other product sales, which include Vemlidy® (tenofovir alafenamide 25 mg), Viread® (tenofovir disoproxil fumarate 300 mg), Letairis, Ranexa, Zydelig® (idelalisib 150 mg), AmBisome® (amphotericin b liposome for injection 50 mg/vial), Cayston® (aztreonam for inhalation solution 75 mg/vial) and Jyseleca® (filgotinib), increased 7% to $498 million for the fourth quarter 2020, compared to the same period in 2019, primarily due to higher sales volume of Vemlidy in other international locations"
Bron: Gilead 4 februari 2021